Origimm Biotechnology

Origimm received a grant from the Austrian leading public funding agency for translational research in Austria, Forschungs-Förderungs-Gesellschaft (FFG) to support the development of a vaccine against P. acnes, the bacterium that causes acne and implant-associated infections.
This significant milestone validates the innovative approach which Origimm is taking to prevent and treat common acne and hospital infections caused by P. acnes; and it underlines the significance of the medical problem that Origimm is addressing.

To celebrate our continuous success in both research and business development, we invited our existing shareholders and interested new investors to our annual Open House event. We presented to them our major achievements and our plan for the future. The event was also considered as the kick-off for our next fundraising round.